Aditxt Balance Sheet Health
Financial Health criteria checks 4/6
Aditxt has a total shareholder equity of $4.4M and total debt of $9.0M, which brings its debt-to-equity ratio to 202%. Its total assets and total liabilities are $29.8M and $25.4M respectively.
Key information
202.0%
Debt to equity ratio
US$8.99m
Debt
| Interest coverage ratio | n/a |
| Cash | US$328.60k |
| Equity | US$4.45m |
| Total liabilities | US$25.39m |
| Total assets | US$29.84m |
Recent financial health updates
Recent updates
Aditxt gains on regaining compliance with Nasdaq listing requirements
Sep 29Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split
Sep 13Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Jul 08Aditxt adds Lauren Chung to board of directors
Jun 18Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring
Dec 14We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth
Nov 23
Financial Position Analysis
Short Term Liabilities: ADTX's short term assets ($2.1M) do not cover its short term liabilities ($24.4M).
Long Term Liabilities: ADTX's short term assets ($2.1M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: ADTX's net debt to equity ratio (194.6%) is considered high.
Reducing Debt: ADTX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADTX has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ADTX is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.